← All trials
NCT04603131
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 17, 2017
- Primary completion
- Jan 30, 2018
- Completion date
- Jul 30, 2018
- First posted
- Oct 26, 2020
- Last posted
- Oct 28, 2020
- Enrollment
- 60
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bharat Biotech International LimitedLead sponsor
- Bharat Biotech International LimitedStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.